Results 241 to 250 of about 2,584,993 (291)

Chinese crop diseases and pests named entity recognition based on variational information bottleneck and feature enhancement. [PDF]

Sci Rep
Huang R, Li M, Zheng H, Zhao Z.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Chinese medical named entity recognition integrating adversarial training and feature enhancement. [PDF]

Sci Rep
Zhang X, Kao Y, Che S, Yan J, Zhou S, Guo S, Wang W.   +6 more
europepmc   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

Chinese medical named entity recognition based on multimodal information fusion and hybrid attention mechanism. [PDF]

PLoS One
Luo Z, Che J, Ji F.
europepmc   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Microllm: a structured information extraction tool using large language models and named entity recognition in microbiology. [PDF]

Brief Bioinform
Lu J, Li F, Feng L, Yu Z, Lu J, Qin M, She S, Jiang H, Guo Z, Xia J, Han L.   +10 more
europepmc   +1 more source

Span-based annotation framework for LLM-based clinical named entity recognition: development and validation using Korean emergency department notes. [PDF]

JAMIA Open
Jang EH, Aguirre J, Lee S, Moon H, Cha WC.   +4 more
europepmc   +1 more source

Nested named entity recognition in traditional Chinese medicine electronic medical records via dual-granularity feature augmentation and span classification. [PDF]

Sci Rep
Minghao L, Qing Y, Chunlei C, Peng L.
europepmc   +1 more source